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Introduction
Thyroid cancer is a common endocrine malignancy that encompasses several histological subtypes including papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), poorly differentiated thyroid cancer (PDTC), medullary thyroid cancer (MTC) and anaplastic thyroid cancer (ATC) [1] . Around 80% of all thyroid cancers are PTCs and these are usually curable with a 5-year survival of over 95% [2] . In contrast, ATC is less frequent and is one of the most aggressive solid tumours with a median survival of 3-5 months. ATCs are highly proliferative, easily invade neck structures and metastasize to distant organs, being usually resistant to conventional chemotherapy and external beam radiotherapy [3] [4] [5] .
Several patients with ATC have a previous history of PTC and in some cases both tumour types coexist. This has led to the hypothesis that ATC derive from PTC through tumour progression [4] [5] [6] [7] [8] [9] . Moreover, the increased incidence of mutations in genes of the RAS-MAPK and PI3K-AKT signalling pathways as well as in the TP53 gene observed in ATCs suggested that ATCs derive from PTCs through the progressive accumulation of a number of genomic alterations [6] . However, the clinical behaviour of ATC and PTC is greatly different [10] . While ATC is nearly uniformly fatal with extremely poor prognosis, PTC is a more benign disease with excellent cure rates. In addition, ATCs can arise with no previous detectable PTCs. These observations are in contrast to the hypothesis of the multistep evolution of ATC from PTC [6, 10, 11] . The disconnection between the clinical behaviour of ATC and PTC and the proposed model of the progressive development of ATC from PTC warrants further investigation.
In order to address this question, we decided to compare the genomic alterations present in ATCs and PTCs and study the potential evolution of both tumour types. Tumours evolve following Darwinian forces and the genomic subclonal behaviour follows a branched evolution in concordance with the 'survival of the fittest' concept. Gene mutations can be considered trunk or branch mutations depending on whether they are clonal or subclonal [12] [13] [14] . Trunk mutations are clonal, enriched in tumourinitiating mutations and are present in a common ancestral cell. Branch mutations are subclonal and can provide information about the expansion of divergent evolution [12] [13] [14] .
We analysed ATCs and PTCs including three pairs of ATCs and PTCs that coexisted in the same patient. The possibility of comparing concomitant ATCs and PTCs was a unique opportunity to evaluate how ATC progress from PTC. We observed a striking genomic difference between the ATCs and PTCs with very few shared trunk mutations. This indicated that ATCs diverge from PTCs early in tumour development suggesting that instead of a progressive development of ATC from PTC, ATC and PTC evolve independently.
Methods

Patients, exome sequencing and data analysis
Fourteen patients with ATC provided tumour and normal DNA for exome-sequencing in this study. Informed consent was obtained from all patients and the research was approved by the local institutional review board/ethics committee of the Vall d'Hebron University Hospital. Three patients exhibited concomitant ATC and PTC components that were macroscopically separated before the analysis of both components (supplementary Table S1 , available at Annals of Oncology online).
DNA was isolated from fresh-frozen and paraffin-embedded samples using the QIAmp DNA Mini kit (Qiagen, Valencia, CA), Qiamp DNA Micro kit (Qiagen, Valencia, CA), Qiamp DNA FFPE Tissue Kit (Qiagen, Valencia, CA) or cobas V R DNA Sample Preparation Kit (Roche, Diagnostics, Mannheim, Germany) according to the respective manufacturer's protocol. DNA libraries were prepared using the Agilent SureSelect XT Library Prep Kit according to the manufacturer's protocol. Target enrichment was carried out using the Agilent SureSelect XT Human All Exon v5 capture set. Sequencing with 100-base paired-end reads of targeted enrichment libraries was carried out on the HiSeq 2500 sequencer. A quality check of the raw data was carried out by the FastQC tool (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Reads were mapped to the Sanger human reference (hg19) by bwa (v. 0.6.2) [15] with default settings. The resulting BAM files were processed using SAMtools (v. 0.1.19) [16, 17] and the Genome Analysis ToolKit (GATK) release 3.2.0 [18] . In brief, BAM files were binary compressed, sorted and indexed by SAMtools (samtools view, sort and index tools), duplicated reads were then removed by the SAMtools function rmdup, and base quality score recalibration and local realignment around indels followed the recommended workflow of the GATK toolkit (RealignerTargetCreator, IndelRealigner, BaseRecalibrator and PrintReads) [19, 20] . Using pileup files from a matched tumour-normal pair, somatic variants were called by VarScan (v2.3.7) function 'somatic' [21] with the following parameters: minimum variant allele frequency (VAF) of 5%, a minimum coverage of 10 reads, at least five reads that confirm the mutation and a P-value <0.05. Annotation of the vcf files was carried out with the software ANNOVAR [22] . Variants were filtered: variant position must be annotated as exonic by RefSeq (Release 45), and synonymous/non-synonymous calls were made and the synonymous excluded from further analysis. All filtering was carried out using in-house parsers.
In order to integrate and compare our results, we made use of TCGA data: when available, mutation and CNA data of ATCs [23] and papillary thyroid carcinoma [24] were analysed together with our data.
Cancer cell fraction (CCF) values were obtained using the formula [25] CCF
where U ¼ tumor purity, C Mut ¼ mutant allele copy number and C Tot ¼ total copy number. Genes mutation frequencies in PTC and ATC were compared by chisquare test, while CCF values of common genes were compared by Student's t-test. All the statistical analyses and plots were carried out with R and RStudio.
Copy number variations (CNVs) were identified using the tool SeqGene [26] . This interface of the R Bionconductor DNAcopy package [27] was used to detect CNV from exome-Seq data comparing a tumour sample with its normal sample.
Phylogenetic trees were produced using the dist.gene (Pairwise Distances from Genetic Data) and nj (Neighbor-Joining Tree Estimation) functions in R package 'ape' [28, 29] .
Driver mutations were identified making use of the Cancer Genome Interpreter and shown in Figure 1 .
Whole-exome sequencing data have been deposited in the European Nucleotide Archive under accession number PRJEB24697.
Mutation analysis by droplet digital PCR
Ten nanograms of genomic DNA extracted from tumour tissues and germline DNA from peripheral blood lymphocytes or non-affected tissue from the same patient was used for digital PCR analysis. Primer sequences are provided in supplementary Table S2 , available at Annals of Oncology online. The reaction was carried out using the QX200 Droplet Digital PCR system (Bio-Rad, Pleasanton, CA) according to manufacturer's protocols and the literature [31] . Mutant populations were identified and fractional abundance calculations of mutant to total molecules were generated for each sample along with a 95% confidence interval using Poisson statistics from the QuantaSoft software as described previously [32] .
Immunohistochemistry and immunofluorescence
Immunohistochemistry (IHC) and immunofluorescence staining was carried out on 4-mm sections from formalin-fixed, paraffin-embedded tumour samples. Primary antibodies anti-p53 (FL-393) (Santa Cruz, Dallas, TX, USA) and anti-BRAFV600E (VE1) (SpringBio, Pleasanton, CA, USA) were used following the manufacturer instructions.
Results
We sequenced three cases of thyroid tumours (and the corresponding normal DNA from peripheral blood mononuclear cells) where an ATC component was present concomitantly with a PTC component. These cases provided an opportunity to compare ATCs and PTCs in the context of the same patient and allowed to determine the degree of divergence of both tumour types. We separated the ATC component from the PTC component and carried out exome sequencing of the ATC and PTC DNA samples as well as normal DNA to determine the CCF of the somatic mutations integrating VAFs, CNVs and the tumour purity. No major differences were observed in CNVs. Strikingly, a large majority of somatic mutations identified were unique for each of the components of the tumour with very few common mutations ( Figure 1A-C) . This indicated that few trunk mutations were shared between ATC and PTC. Phylogenetic trees were carried out and we observed that the trunk of the tree of the three cases was much shorter than the actual branches of the ATC and PTC tumours ( Figure 1A-C) . Although we observed that a mixture of ATC and PTC subclones was present in patient 2, we carried out in this case the phylogenetic tree following the somatic gene mutations that exhibited the highest CCFs. The long branches of the phylogenetic trees in the three cases suggested a large divergence between ATC and PTC. In order to validate the results from the exome sequencing we carried out droplet digital PCR (ddPCR) of gene mutations with high CCFs present in the PTC, ATC or trunk of the three pair of cases. The CCFs of the gene mutations determined by exome sequencing were similar to the ones observed by ddPCR confirming our results ( Figure 1D ).
In the case of patient 2, we observed that a group of gene mutations were present in the PTC component at higher CCFs than in ATCs (see Figure 1B) . We proposed that the ATC component contained a proportion of the PTC cells. We observed that in this patient the ATC component exhibited a p53 C135Y mutation while the PTC component showed a BRAF V600E mutation the CCF of which was decreased in the ATC component. This suggested that within the ATC component some PTC cells with the BRAF V600E mutation were present. We took advantage of antibodies that specifically recognise BRAF V600E and the fact that mutant p53 is highly expressed in tumours and carried out IHC and immunofluorescence analyses. The PTC component presented an homogeneous staining of BRAF V600E and no staining of p53 (Figure 2) . This confirmed the presence of BRAF V600E and the absence of p53 C135Y in the PTC component. When analysing the ATC component, we observed a subset of cells expressing BRAF V600E and, interestingly, a different group of cells expressing p53 (Figure 2) . The proportion of BRAF V600E-positive cells varied depending on the analysed tumour region. No cell co-expressed BRAF V600E and p53. This supported the hypothesis that PTC cells (BRAF V600E positive, p53 negative) were present within the ATC component. Since we observed that the p53 and BRAF mutations were in different clones we included them in different arms of the phylogenetic tree.
In order to support our results in a large patient cohort, we carried out exome sequencing of 11 ATC samples (in addition to the three cases described already) and integrated our results with the sequencing data from TCGA [23, 33, 34] . In total, we analysed 44 cases focusing in gene mutations including truncating, inframe and missense mutations ( Figure 3A) . We carried out the same type of analysis in PTCs using in this case the publicly available data from TCGA (401 cases) [24] (Figure 3B ). No major differences were observed in CNVs, however, we observed that the gene mutation frequencies in ATC and PTC were statistically different using a chi-square test (P ¼ 4.8 Â 10
À5
) indicating that ATCs and PTCs exhibit a large degree of molecular divergence.
We represented the 25 genes with the highest CCFs in ATC, both for ATC and PTC ( Figure 3A) We then plotted the average CCF of the 25 most frequently mutated genes in ATCs for which at least three mutations were present in both PTCs and ATCs (Figures 3B). We carried out a Student's t-test and found that the average CCF of the BRAF, NRAS, KMT2A and HRAS mutations was statistically higher in PTCs than in ATCs ( Figure 3B ). To discard that the tumour purity could impact on the CCF values, we redid the analysis with samples that exhibit 80% of purity or higher. Again, we observed a statistical difference in CCF values between ATC and PTC (P ¼ 9.3 Â 10 À14 ). Overall, our results showed differences in genes exhibiting high CCFs (enriched in trunk mutations) in ATCs and PTCs suggesting that ATCs might not derive from PTCs by accumulating a small number of new genomic alterations.
In summary, our data showed a significant difference in the genomic alterations between ATC and PTC implying a large divergent evolution of both tumour types.
Discussion
The recent advances in sequencing technologies are facilitating the answer to unresolved questions, including mechanisms of oncogenesis, intra-tumour heterogeneity, mechanisms of resistance to treatment and many others. We decided to apply nextgeneration sequencing to study thyroid cancer. The most accepted hypothesis in the field considers that ATC derives from PTC through the acquisition of a discrete number of genomic alterations including mutations in members of the RAS-MAPK and PI3K-AKT pathways as well as TP53 [4] [5] [6] [7] [8] [9] . We decided to validate this hypothesis through the genomic analysis of ATCs and PTCs including three cases where ATCs and PTCs were simultaneously present in the same tumour specimen.
The sequencing of three pairs of ATC-PTC concomitant cases offered a great opportunity to assess whether in the same patient ATC derived from PTC. We observed a large genomic divergence between ATCs and PTCs in the three paired cases. The common trunk mutations were extremely few and the ATC and PTC branches were long with many gene mutations. We then analysed the data originated from the sequencing of 44 ATCs (including the 14 ATC cases from our own sequencing efforts) and 401 PTCs found in public data bases [23, 24, 33, 34] . Importantly, we observed that the gene mutations with the highest CCFs in ATCs and PTCs were not the same. Trunk mutations are gene mutations present in the majority of tumour cells and, hence, with a high CCF. These mutations are then clonal and originated in a common ancestral cell. The fact that most of the high incidence/ high CCF gene mutations were not the same between ATCs and PTCs indicated that trunk mutations differ and hence both tumour types are largely divergent. BRAF and NRAS were two genes frequently mutated in both tumour types. Based on the hypothesis that ATCs progress from PTCs, the incidence and CCFs of BRAF and NRAS should be similar in both thyroid tumours. However and interestingly, both gene mutations have a higher incidence and CCFs in PTCs than in ATCs. In agreement with these observations, some genomic alterations have been described to be specific of ATCs or PTCs. For example, previous work analysing the prevalence of RET rearrangements showed that these genomic alterations are exclusively found in PTCs and not ATCs discarding in this case that ATCs derive from RET mutant PTCs [35] .
Our results impact on the hypothesis that claims that ATCs are derived from PTCs through the acquisition of a discrete number of gene mutations. Instead, the long divergent evolution that we observed when comparing ATCs and PTCs indicates that the two Oncoprint plots represent mutations along patients: orange and brown squares represent truncating mutations, yellow and salmon in-frame mutations and blue missense mutations. B, Barplot of average cancer cell fraction (CCF) of the genes from A for which at least three mutations are present in both PTCs and ATCs. Data are represented as mean 6 SD, ***P < 0.001 using Student's t-test. tumour entities were separated long before the tumour was diagnosed and surgically resected. This opens novel questions to explain the observations. We could postulate the hypothesis that ATC and PTC arise from a slow cycling cell [maybe a thyroid stem cell (TSC)] possibly during fetal development [36] and that are kept dormant through the years partially maintaining its capacity to differentiate into a progeny. TSCs and its differentiated offspring cells will keep accumulating mutations independently till becoming tumours. ATCs might derive from more undifferentiated TSCs while PTCs could derive from more differentiated cells (Figure 4) .
Our study shows that ATCs and PTCs are two molecularly separated entities. These two tumour types not only exhibit diverse clinical behaviours but show strong genomic differences. This has obvious clinical implications since the management of ATC and PTC should be adapted to the actual molecular characteristics of the tumours. The understanding of the oncogenesis of ATCs sheds light on to the complexity of thyroid cancer and will facilitate the development of better therapies to tackle this dismal disease. 
